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PXPEDITED REVIEW
reatment of Calcific Aortic
tenosis With the Percutaneous Heart Valve
id-Term Follow-Up From the Initial
easibility Studies: The French Experience
lain Cribier, MD, FACC,* Helene Eltchaninoff, MD,* Christophe Tron, MD,* Fabrice Bauer, MD,*
arla Agatiello, MD,* Deborah Nercolini, MD,* Sydney Tapiero, MD,* Pierre-Yves Litzler, MD,†
ean-Paul Bessou, MD,† Vasilis Babaliaros, MD*
ouen, France
OBJECTIVES The aim of this work was to study the feasibility, safety, efficacy, and durability of
percutaneous heart valve (PHV) implantation in the aortic position.
BACKGROUND We developed a PHV (equine pericardium valve in a balloon-expandable, stainless-steel
stent) to treat patients with inoperable aortic stenosis (AS).
METHODS Thirty-six patients (aortic valve area 0.7 cm2, New York Heart Association [NYHA]
functional class IV, and severe comorbidities), formally declined for surgery, were recruited on
a compassionate basis. The PHV was implanted by retrograde or antegrade trans-septal
approach. Clinical and echocardiographic outcomes were assessed serially.
RESULTS Twenty-seven patients were implanted successfully (23 antegrade, 4 retrograde) in the
subcoronary position with improvement in valve area (0.60  0.11 cm2 to 1.70  0.10 cm2,
p  0.0001) and transvalvular gradient (37  13 mm Hg to 9  2 mm Hg, p  0.0001).
Paravalvular aortic regurgitation was grade 0 to 1 (n  10), grade 2 (n  12), and grade 3
(n  5). One week post-procedure, improvement in left ventricular function (45  18% to
53  14%, p  0.02) was most pronounced in patients with ejection fraction 50% (35 
10% to 50 16%, p 0.0001). Thirty-day major adverse events after successful implantation
were 26% (pericardial tamponade, stroke, arrhythmia, urosepsis, and one death unexplained
at autopsy). Eleven patients are currently alive with follow-up of 9 months (n 2), 10 months
(n  3), 11 months (n  1), 12 months (n  2), 23 months (n  1), and 26 months (n 
2). All patients experienced amelioration of symptoms (90% NYHA functional class I to
II). Percutaneous heart valve function remained unchanged during follow-up, and no deaths
were device-related.
CONCLUSIONS Percutaneous heart valve implantation is feasible in inoperable patients with end-stage AS
leading to hemodynamic and clinical improvement. Continued advances and improved
patient selection should decrease adverse events in the near future. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.0492006;47:1214–23) © 2006 by the American College of Cardiology Foundation
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cortic stenosis, the most common form of valvular heart
isease in adults (1), affects thousands of patients every year,
ausing significant morbidity and mortality in those with
dvanced disease. To date, surgical valve replacement is the
nly effective therapy for these patients, improving survival
nd ameliorating symptoms (2). However, almost one-third
f patients with severe valvular lesions who could benefit
ost from intervention are declined for operative treatment
ecause of end-stage disease, advanced age, and multiple
omorbidities with subsequent short life expectancy (1). The
ize of this untreated cohort is expected to increase in the
ext several years reflecting the aging population and
From the University of Rouen, *Department of Cardiology and †Department of
ardiac Surgery, Charles Nicolle Hospital, Rouen, France. Financial support was
rovided by Percutaneous Valve Technologies Inc. Edwards Lifesciences (Irvine,
alifornia), the company that designed and provided the percutaneous valve used,
rovided funding for this clinical investigation.c
Manuscript received December 20, 2005; revised manuscript received January 19,
006, accepted January 24, 2006.mproving therapeutic options in patients with multiple and
dvanced medical conditions.
The initial attempts to treat non-surgical patients with
dvanced aortic stenosis began with balloon aortic valvuloplasty
BAV) in 1985 (3). This technique, initially met with enthu-
iasm, was largely abandoned by clinicians as the benefits of
alvuloplasty rarely lasted more than one year (4). The problem
f valve restenosis after balloon dilation was finally addressed in
999 with the development of a bioprosthetic heart valve,
hich was sutured onto a balloon expandable stent (Percuta-
eous Valve Technologies, Edwards Lifesciences, Irvine, Cal-
fornia) (Fig. 1). Though previous attempts at percutaneous
alve replacement in the aortic position had been limited by the
pplicability to humans (5,6), this percutaneous heart valve
PHV) was successfully implanted on April 16, 2002, in a
atient with inoperable aortic stenosis and life-threatening
omorbidities (7).
Since then, improvements in technique and a moreomplete comprehension of percutaneous aortic valve re-
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March 21, 2006:1214–23 Mid-Term Experience of Percutaneous Heart Valvelacement have been developed and partially reported in six
atients (four patients before the onset of the protocol-
riven study, two patients included in the current analysis)
8). In August 2003, we started a single-center pilot trial to
tudy the feasibility and safety of compassionate percutane-
us valve implantation in patients with end-stage aortic
tenosis and no surgical options (the Initial Registry of
ndoVascular Implantation of Valves in Europe
I-REVIVE] trial). With the acquisition of Percutaneous
alve Technologies (Fort Lee, New Jersey) by Edwards
ifesciences, the protocol continued with minor amend-
ents as the Registry of Endovascular Critical Aortic
tenosis Treatment (RECAST) trial. In the following text
e describe our experience with the initial 36 patients
nrolled in our institution for percutaneous aortic valve
mplantation.
ETHODS
hirty-six elderly patients that were able to give informed
nd signed consent were recruited for percutaneous valve
mplantation at Charles Nicolle Hospital, University of
ouen, France. Eligibility for entry into the study required
he presence of severe aortic valve stenosis (0.7 cm2) with
ssociated symptoms (by New York Heart Association
NYHA] functional class IV dyspnea) that were expected to
Abbreviations and Acronyms
AVA  aortic valve area
BAV  balloon aortic valvuloplasty
I-REVIVE  Initial Registry of EndoVascular
Implantation of Valves in Europe trial
MACCE  major adverse cardiac and cerebrovascular
events
MI  myocardial infarction
NYHA  New York Heart Association
PHV  percutaneous heart valve
RECAST  Registry of Endovascular Critical Aortic
Stenosis Treatment trial
TTE  transthoracic echocardiography
igure 1. (A) Top view of the percutaneous heart valve in the closed posit
ide view of the percutaneous heart valve crimped over a 3-cm  22-mm bal
xpanded by the delivery balloon.enefit from isolated valve replacement. Patients had to be
efused for standard aortic valve replacement by two inde-
endent cardiac surgeons on the basis of their high risk for
urgery (Parsonnet’s score 30) (9). Exclusion criteria
ncluded the following: vascular disease that precluded
ccess, severe deformation of the chest, intracardiac throm-
us, unprotected stenosis of the left main coronary artery
ot amenable to percutaneous intervention, myocardial
nfarction (MI) within seven days, prosthetic heart valves,
ctive infection, leukopenia (3,000 white blood cells/
m3), coagulopathy, active bleeding, or acute anemia (he-
oglobin9 mg/dl). Patients that could not be fully dilated
ith a 23-mm aortic valvuloplasty balloon (notable waist)
nd patients with a native aortic valve annulus size24 mm
r 19 mm were also excluded. The study was approved
nd performed in accordance with the regulations of our
nstitutional ethics committee (CCPPRB, Comité Consul-
atif de Protection des Personnes dans la Recherche Bio-
édicale) and the French government (AFSSAPS,
gence Francaise de Sécurité Sanitaire des Produits de
anté).
efinitions and baseline measurements. The primary
bjectives of this study were to evaluate the feasibility and
afety of PHV implantation. Feasibility was evaluated by
rocedural success defined as accurate placement of the
HV in the subcoronary position with associated improve-
ent of hemodynamic parameters (30% reduction in
ean transvalvular aortic gradient) and absence of severe
ortic regurgitation (grade 4) (10). Safety was evaluated by
he occurrence of major adverse cardiac and cerebrovascular
vents (MACCE) or other valve-related adverse events.
ajor adverse cardiac and cerebrovascular events were
efined as death, MI, emergent cardiac surgery, and cere-
rovascular accident. Any MACCE that occurred either
uring or within 30 days of PHV implantation was consid-
red a procedure-related complication. Any adverse event
hat was secondary to PHV malfunction after implantation
as considered a device-related complication. Safety was
owing the three pericardial leaflets sutured to the stainless-steel stent. (B)ion sh
loon catheter. (C) Side view of the percutaneous heart valve after being
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Mid-Term Experience of Percutaneous Heart Valve March 21, 2006:1214–23ssessed at 1, 3, 6, and 12 months; after 1 year, patients were
ollowed every 6 months.
The secondary objectives of the study were to obtain data
egarding the efficacy and durability of the PHV. Efficacy
nd durability were assessed by NYHA functional classifi-
ation and hemodynamic improvement (measured by echo-
ardiography). Hemodynamic variables, such as native and
rosthetic aortic valve gradient, area, and regurgitation
valvular or paravalvular, graded from 0 to 4) (10), were
valuated by standard methods of echocardiographic mea-
urement. Clinical evaluation and echocardiographic exam-
nation were performed immediately post-procedure, on day
, day 7, 1 month, 3 months, 6 months, and 12 months;
fterwards, patients were followed every 6 months.
Valve anatomy and function were determined in all
atients by transesophageal echocardiography and transtho-
acic echocardiography (TTE) pre-procedure; coronary
natomy was also evaluated pre-procedure. In addition to
chocardiographic measurements, right-sided heart pres-
ures, cardiac output, oxygen saturations, and aortic trans-
alvular pressure gradient were measured on the day of
mplantation by invasive methods. Valve calcification was
ssessed qualitatively by fluoroscopic evaluation.
rocedure. The materials and technique for implantation
ave been previously described in detail (7,8,11). Briefly,
ach procedure was performed under mild sedation and
ocal anesthesia. All patients received aspirin (160 mg) and
lopidogrel (300 mg) 24 h before valve placement; antibi-
tics for procedural prophylaxis (first generation cephalo-
porin) were given 1 h before. After measurement of
aseline hemodynamics, supra-aortic angiography and
lacement of a right ventricular pacing lead were performed.
eparin 5,000 IU was given intravenously before retrograde
atheterization of the aortic valve. Retrograde pre-dilation
f the aortic valve was done in all patients (except two whoFigure 2. Electrocardiogram and aortic pressure curve depicting the effect of rapere dilated antegrade) with a 23-mm Z-MED balloon
NuMED Inc., Hopkinton, New York) during rapid ven-
ricular pacing (200 to 220 stimulations/min) (Fig. 2).
elivery of the valve was performed by an antegrade
rans-septal or retrograde approach.
In the antegrade approach, atrial trans-septal catheteriza-
ion was performed, and a 7-F Swan-Ganz catheter (Ed-
ards LifeSciences, Irvine, California) was used to cross the
itral valve and direct a guidewire across the aortic valve
Fig. 3A). Using the pigtail catheter as a conduit, this
uidewire was exchanged for an extra stiff guidewire, which
as snared and externalized through the left femoral artery
heath. The septum was then dilated with a 10-mm sep-
ostomy balloon. The PHV was advanced over the guide-
ire through a 24-F sheath (COOK, Bjaeverskov, Den-
ark) in the right femoral vein. A 7-F Sones catheter
Cordis, Miami, Florida) was advanced over the same
uidewire from the left femoral artery to facilitate valve
lacement (Fig. 3B).
In the retrograde approach, pre-closure of the common
emoral artery puncture site was done before introduction of
he 24-F sheath (four patients) using two 10-F Prostar XL
evices (Abbott Vascular Devices, Redwood City, Califor-
ia) (12). After retrograde catheterization of the aortic
alve, the crossing catheter was exchanged for an extra stiff
uidewire, and pre-dilation of the aortic valve was done as
escribed previously. The femoral artery was then pre-
ilated with a series of dilators of increasing size (18-, 20-,
nd 22-F) in order to facilitate entry of the 24-F sheath.
Regardless of the approach used, the final steps of
HV implantation were similar for both methods. The
HV was mounted onto a 22-mm Z-MED II balloon
NuMed Canada Inc., Cornwall, Ontario, Canada) using
specially designed crimper. The supra-aortic angiogram
nd native valve calcifications were used as anatomicalid stimulation (arrows) of the right ventricle (200 to 220 stimulations/min).
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March 21, 2006:1214–23 Mid-Term Experience of Percutaneous Heart Valveandmarks for valve placement in the anteroposterior
rojection (mid-line of the stent frame was placed at the
evel of the calcifications). All valves were deployed (Figs.
C and 3D) during rapid pacing except two patients that
ere implanted during cardiac arrest. Hemodynamic
mprovement was measured immediately afterwards, and
supra-aortic angiogram was performed in patients
ithout renal insufficiency to verify placement as well as
he presence of aortic regurgitation (Fig. 3E). A cranial
iew of the stent-valve was used to evaluate uniform
xpansion of the PHV (Fig. 3F). Arterial access was
igure 3. (A) Swan-Ganz (SG) catheter is used to direct a guidewire (GW)
eft ventricle is tracked by the percutaneous heart valve from the right femoral
o help position the percutaneous heart valve. Native aortic valve calcifications
tent valve. (C) Deployment of the percutaneous heart valve using the antegr
ngiogram showing no aortic regurgitation and the subcoronary position of the
f the percutaneous heart valve showing symmetrical and complete expansionanaged using closure devices and/or surgical repair pefore device use or in cases of device failure. Venous
ccess was managed by manual compression. Antibiotics
ere given up to 48 h after the procedure. Subcutaneous
noxaparin (40 mg/day) was administered until the day of
ischarge. Clopidogrel (75 mg/day) was continued for one
onth, and aspirin (160 mg/day) was continued indefinitely.
tatistical analysis. Comparison of clinical and echocar-
iographic variables with baseline values was performed
sing the non-parametric Wilcoxon rank sum test. Compar-
son of procedural times was done by the Mann-Whitney U
est. Differences were considered statistically significant for
the native aortic valve in the antegrade approach. (B) Guidewire loop in the
antegrade approach). Sones catheter (SC) from the left femoral artery is used
s) in the anteroposterior projection transect the mid-line of the length of the
pproach. (D) Valve deployment via the retrograde method. (E) Supra-aortic
taneous heart valve (arrow: filling of the left coronary artery). (F)Cranial view
e stent frame. MS Mullins sheath; PL  pacing lead.across
vein (
(arrow
ade a
percu 0.05. All values were expressed as mean  SD.
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Mid-Term Experience of Percutaneous Heart Valve March 21, 2006:1214–23ESULTS
atient characteristics. Characteristics of the patients re-
ruited are shown in Table 1. In addition to their age and
able 1. Baseline Characteristics of Patients
Characteristics n (%)
ge, yrs 80  7 (range 62–91)
85 yrs 9 (24)
ender, male 21 (57)
jection fraction
50% 11 (30)
31%–50% 15 (42)
30% 10 (28)
ardiogenic shock 2 (5)
oronary artery disease 28 (76)
CABG surgery 8 (22)
Previous MI 7 (19)
iabetes mellitus 12 (32)
ypertension 26 (70)
enal failure* 14 (38)
evere lung disease 15 (41)
ulmonary hypertension† 14 (38)
eripheral vascular disease 10 (27)
Porcelain aorta 2 (5)
Carotid disease 4 (11)
revious stroke 3 (8)
itral valve disease 12 (32)
 grade 3 regurgitation 10 (27)
 moderate stenosis 2 (5)
ctive cancer 2 (5)
revious chest irradiation 4 (11)
ther comorbidity 22 (59)
arsonnet’s score 47  9
uroSCORE 12  2
Serum creatinine 2 mg/dl or creatinine clearance 30 ml/min. †Mean pulmonary
rtery pressure 30 mm Hg or systolic pulmonary artery pressure 60 mm Hg.
CABG  coronary artery bypass grafting.igure 4. Schematic representation of patient enrollment and procedural success
nitial retrograde failure). PHV  percutaneous heart valve.nd-stage aortic stenosis, these patients had extensive and
ultiple comorbid conditions (3 per patient). Other
ignificant comorbid conditions not detailed in the table
ncluded severe kyphoscoliosis, severe osteoporosis, hepatic
irrhosis, systemic scleroderma, angiodysplasia of the colon
ith chronic anemia (hematocrit 30%), myelodysplastic
yndrome with chronic anemia, chronic steroid use, an-
iphospholipid syndrome with previous thrombotic history,
eripheral neuropathy, severe obesity, severe right heart
ailure, and Parkinson’s disease. One patient was a Jehovah’s
itness. All native aortic valves were tricuspid and calcified
12 heavy, 17 moderate, 7 mild).
rocedural success. Of the 36 patients enrolled, 35 pa-
ients were taken to the catheterization laboratory (Fig. 4):
patient died of sudden cardiac death while awaiting his
rocedure. After pre-dilation, one procedure was cancelled
ecause the annulus size was inappropriately large for a
3-mm PHV (the 23-mm balloon could not be stabilized in
he native valve during valvuloplasty). One patient in
ardiogenic shock arrested during pre-dilation of the aortic
alve and had an unsuccessful resuscitation. Among 33
atients, the antegrade trans-septal approach was used in 26
ases, and retrograde implantation was attempted in the
emaining 7 cases. Twenty-two of the antegrade implanta-
ions were performed successfully with four technical fail-
res. Two of these patients could not hemodynamically
olerate the guidewire across the mitral valve, and the
rocedure was aborted before proceeding to valve implan-
ation. In the other two patients, PHV migration occurred
mmediately after implantation. In one case of migration,
he PHV was positioned too high, and in the other case, the
ative valve was only mildly calcified with a large annulus(*Patient #16 was implanted successfully by the antegrade approach after
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March 21, 2006:1214–23 Mid-Term Experience of Percutaneous Heart Valve23 mm). In both situations, the PHV was deployed in the
orta (thoracic descending aorta in one, and between the left
ommon carotid and left subclavian artery in the other)
ithout sequelae. In all cases of technical failure, the
atients were discharged from the catheterization laboratory
n stable condition.
Four of seven patients were successfully implanted using
he retrograde method. Of the three technical failures, one
atient could not be implanted because the stent-mounted
atheter was too short to reach the aortic valve (PHV
emoved surgically from the femoral artery). Two of the
atients’ valves could not be crossed retrograde with the
elivery system because of extensive calcification, and the
HV was implanted in the descending aorta without
equelae. In one of these cases, the PHV was successfully
mplanted by the antegrade approach in the same session. A
otal of 27 (75%) patients were implanted successfully.
he procedural time for the antegrade approach was 164
38 min in the I-REVIVE trial and 130  30 min in
he RECAST trial (p  0.047). No detectable atrial
hunt could be measured by oximetry at the end of the
rocedure. Procedural time for the retrograde approach
only I-REVIVE patients) was 96  23 min.
chocardiographic data. A statistically significant increase
n aortic valve area (AVA) was seen in the group of patients
ith successful implantation. Twenty-four hours after the
rocedure, the AVA, measured by TTE, increased from
.60  0.09 cm2 to 1.70  0.11 cm2 (p  0.0001, n  25
igure 5. (A) Improvements in aortic valve area in patients 24 h, 1, 3, 6,
radient in patients 24 h, 1, 3, 6, 12, and 24 months after successful implantaturviving patients). At 1, 3, 6, 12, and 24 months, the AVA
emained stable at 1.68  0.11 cm2 (n  16), 1.66  0.09
m2 (n  12), 1.63  0.07 cm2 (n  7), 1.75  0.18 cm2
n  3), and 1.64  0.04 cm2 (n  2), respectively (p  NS)
Fig. 5A). Similarly, the mean aortic gradient decreased
rom 37  13 mm Hg to 9  2 mm Hg post-procedure
p  0.0001, n  25), and remained 10  2 mm Hg, 11 
mmHg, 11 2 mmHg, 10 1 mmHg, and 12 1 mm
g (1, 3, 6, 12, and 24 months, respectively) during
ollow-up (p  NS) (Fig. 5B). Peak velocity across the
ortic valve decreased from 4.01  0.60 m/s to 2.25  0.40
/s post-implantation (p  0.0001), and was 2.36  0.25
/s, 2.45  0.25 m/s, 2.42  0.31 m/s, 2.33  0.11 m/s,
nd 2.36  0.17 m/s upon follow-up (p  NS).
The ejection fraction also improved significantly in the
atient group with a successful implantation. Left ventric-
lar function was 45  18% pre-procedure and 53  14%
Fig. 6A) one week post-procedure (n 22, p 0.02). The
ost dramatic improvements were seen in patients that had
epressed function at baseline (Fig. 6B). In these 15
atients, the ejection fraction (35 10%) increased to 50
6% (p  0.0001) at one week.
Aortic regurgitation in patients after implantation was
lways paravalvular in origin. In 10 patients, the regurgita-
ion was mild (grade 0 to 1). In 10 patients, moderate (grade
) paravalvular leak was observed, and in 5, moderate-to-
evere regurgitation was noted (grade 3). In the two patients
ithout post-procedure echocardiography, aortic insuffi-
nd 24 months after successful implantation. (B) Decrease in mean aortic
ion.
c
v
u
o
p
s
a
C
i
p
o
h
o
s
p
s
t
t
C
c
p
d
c
s
t
t
e
a
t
w
p
c
s
t
t
t
1
f
c
c
l
m
t
w
A
m
F plan
v left v
1220 Cribier et al. JACC Vol. 47, No. 6, 2006
Mid-Term Experience of Percutaneous Heart Valve March 21, 2006:1214–23iency was grade 2 by angiography. The amount of para-
alvular leak was unchanged in most patients during follow-
p. In two patients, an improvement of paravalvular leak by
ne grade was seen three months after the procedure. In two
atients, an increase of paravalvular leak by one grade was
een after one week. No atrial shunt was visualized by TTE
t three-month follow-up.
linical follow-up. Six of the 27 patients with PHV
mplantation had a complication during the procedure. Two
atients died as a consequence of cardiac tamponade. One
f these patients, with severe dextrorotation of the heart,
ad a complicated trans-septal puncture. The other patient,
n chronic steroid therapy for pulmonary fibrosis, had a
low bleeding perforation of the right ventricle from the
acing lead; infection and subsequent sepsis developed after
urgical repair. Another patient on chronic steroids for
reatment of rheumatologic disease developed urosepsis
hree days after the procedure and died two days later.
omplete heart block with temporary loss of pacing lead
ontact occurred in one case; despite successful PHV im-
lantation, prolonged resuscitation lead to irreversible brain
amage. One patient developed a stroke during retrograde
atheterization of the aortic valve. She expired at 33 days
igure 6. (A) Improvement in ejection fraction one week after successful im
alues with values one week after successful implantation in patients withecondary to multi-organ failure. Intractable hypotension in dhe procedure room after removal of the 24-F sheath from
he femoral artery was the cause of another death. No
tiology was found at autopsy; the PHV appeared normal
nd appropriately positioned (Table 2).
The remaining 21 patients with successful PHV implan-
ation experienced remarkable amelioration of symptoms
ith improvements in functional class. Five patients im-
roved to NYHA functional class I; 14 improved to NYHA
lass II, and 2 improved to NYHA class III (limited by
evere lung disease). Despite their improvements, however,
heir advanced comorbid conditions limited the extent of
heir survival. One patient with severe right and left ven-
ricular dysfunction died of a ventricular arrhythmia at day
8 post-procedure. Three patients died of progressive renal
ailure at two months. Three patients died of a non-cardiac
ause during a prolonged and complicated postoperative
ourse (toe amputation at 2 months, revascularization of the
ower extremities at 3 months, and orthopedic surgery at 5.5
onths). Third-degree heart block developed in one patient
hree months after the procedure. Pacemaker implantation
as complicated by pulmonary embolus, sepsis, and death.
nother patient expired at three months secondary to pneu-
onia. One patient with underlying metastatic breast cancer,
tation (n  22). (B) Improvement in ejection fraction comparing baseline
entricular function 50% (n  15).ied with a morphine overdose (3.5 months), (Table 2).
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March 21, 2006:1214–23 Mid-Term Experience of Percutaneous Heart Valveevice-related complications (0% occurrence in this study)
ere not a cause of death in any of these cases.
To date, 11 patients are alive (3 from the I-REVIVE
rial, 8 from the RECAST trial) and have returned to a
ormal life, limited only by their previous medical condi-
ions (NYHA functional class I in 4 patients, class II in 6
atients, class III in 1 patient). Their follow-up is 9 months
n  2), 10 months (n  3), 11 months (n  1), 12 months
n  2), 23 months (n  1), and 26 months (n  2). The
alve function by the most recent echocardiographic exam
valve area 1.69  0.10 cm2, mean transvalvular gradient
1  3 mm Hg, measured at 3 to 24 months post-
rocedure) is unchanged compared to the day of implanta-
ion (valve area 1.72  0.13 cm2, mean transvalvular
radient 9  3 mm Hg, p  NS). The amount of
aravalvular leak in these patients is grade 0 to 1 (n 7) and
rade 2 (n 4). Ejection fraction in this group is 53 12%
baseline 51 15%, p NS). One patient has not returned
or repeat TTE, but remains clinically improved.
Seven patients who underwent BAV without a successful
alve implantation or attempted valve implantation, sur-
ived several months after their procedure. One patient
urvived 19 months but suffered from recurrent heart failure,
ultiple strokes, and, eventually, a neurovegetative state.
ne patient died 10 months after dilation, spending most of
er remaining life hospitalized for heart failure. Another
atient died of heart failure (three months), and one
uccumbed to pancreatic cancer (two months). Three pa-
ients are alive at eight, six, and four months post-
rocedure. One (month 8) had return of NYHA functional
able 2. Major Adverse Cardiac and Cerebrovascular
vents (MACCE) at 30 Days and 6 Months After
uccessful Implantation
ACCE at 30 days
Death 6
Tamponade 2
Sepsis 1
Brain death post resuscitation 1
Unknown etiology 1
Ventricular arrhythmia 1
Stroke 1
Myocardial infarction 0
Emergent cardiac surgery 0
Total 7 (26)
ACCE at 6 months*
Death 10
Renal failure 3
Postoperative 3
Pulmonary embolus 1
Pneumonia 1
Cancer 1
Multi-organ failure† 1
Stroke 0
Myocardial infarction 0
Emergent cardiac surgery 0
Total 10 (37)
alues are n (%). *MACCE 30 days not included. †Multi-organ failure death
ccurred at 33 days in the patient who suffered a procedural stroke.lass IV dyspnea. iISCUSSION
uring this phase I trial, we had to develop criteria for
ppropriate patient selection and the optimal technique for
HV implantation, utilizing our experience from animal
odels and previous cases of BAV. The inclusion criteria
mposed for this study resulted in a selection of patients that
ere among the toughest we have intervened upon. Know-
ngly, the learning curve for an innovative procedure such as
his one is steep and is only partly reflected by improvements
n procedural times.
easibility and technique. Twenty-seven patients (82% of
he 33 patients attempted) with debilitating and life-
hreatening aortic stenosis were successfully implanted with
PHV in the subcoronary position without coronary
cclusion or interference of the mitral valve apparatus. Both
he antegrade and retrograde approach were used in the
-REVIVE part of the trial; only the antegrade approach
as used in the RECAST part of the trial (per protocol
mendment). With the antegrade approach, the success rate
as very high (85%), and the problems associated with
ntroducing a 24-F sheath into the femoral artery were
voided (two cases of closure device failure of four at-
empted). It was easier to cross the native valve with the
HV in the antegrade rather than the retrograde direction,
specially in patients with excessive calcification. This ap-
roach, however, was technically more demanding and
equired more case experience. Hemodynamic collapse used
o occur during implantation until we learned that the stiff
uidewire could exert traction on the anterior leaflet of the
itral valve. Straightening of this guidewire loop in the left
entricle caused massive mitral regurgitation and hemody-
amic collapse that recovered only when the loop shape was
esumed. The problems of the guidewire loop were mark-
dly improved by pushing the Sones catheter retrogradely
nto the left ventricle, maintaining the guidewire shape
uring passage of the PHV in the left heart. Guidewire-
nduced hemodynamic collapse, consequently, did not occur
uring PHV implantation in the RECAST trial. In the
-REVIVE trial, however, five patients experienced this
roblem during implantation.
The success of retrograde implantation (57%, four of
even patients) was lower than that of the antegrade
pproach. The procedure, however, was quicker and less
echnically demanding without the problem of guidewire
oops. Many patients were not candidates for this method
ecause of diseased or tortuous femoral arteries that could
ot accommodate such a large sheath size. In some patients
ith heavily calcified valves, we were unable to retrogradely
ross the native valve with the PHV because of wire bias
nto a commissure (the three failures). In this situation, we
ontinued the procedure by the antegrade route in one
atient. When the valve could not be implanted in the heart,
he PHV was surgically removed from the femoral artery
one patient) or safely deployed above the bifurcation of the
liac arteries to avoid the complications of vascular surgery,
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ients). In one of the patients with a valve in the descending
orta, angiographic and clinical follow-up (10 months)
onfirmed the valve in the open position without impedance
o flow. In the other patient, autopsy evaluation revealed the
alve also in the open position without evidence of migra-
ion (12 h). Likewise, in two patients with a failed procedure
econdary to migration, implantation of the PHV in the
horacic aorta was without sequelae (up to six months
ollow-up). In our previous animal experience (A. Cribier
nd H. Eltchaninoff, unpublished data, 2001), the PHV
mplanted in the aorta remains in the open position and is
f no clinical consequence.
In both the antegrade and the retrograde approach, rapid
entricular pacing was fundamental for the success of the
rocedure. At a rate of 200 to 220 beats/min, rapid pacing
auses an immediate and predictable decrease in stroke
olume, preventing the ejection of the PHV-mounted
alloon catheter by the left ventricle. Rapidly pacing the
eart for 10 s during PHV deployment or BAV is well
olerated and has not provoked malignant ventricular ar-
hythmias in our series. The pacemaker lead is also helpful
o prevent episodes of significant bradycardia that can occur
uring the procedure.
afety. Thirty-day MACCE was 26% in those with a
uccessful implantation. Though none of these patients
xpired because of prosthetic valve dysfunction, these deaths
ere related to complications from the procedure. Obvi-
usly, this group was also at an extremely high risk for
urgical valve replacement. A Parsonnet’s surgical risk score
f 47 and a EuroSCORE of 12 has been respectively
ssociated with a25% and20% mortality within 30 days
f cardiac surgery (9,13). The high mortality reflects the
ature of intervening on this precarious group. The rate of
troke in our series (including patients who underwent PHV
mplantation or just BAV with a failed implantation) was
.8% (1 of 35 patients), which is similar to the incidence
eported with surgical valve replacement (14).
The six-month MACCE was also very high (37% ex-
luding MACCE at one month). Even after successful
mplantation with improvement in functional status, many
f our patients (n  10) remained fragile, unable to tolerate
on-cardiac surgery or succumbing to conditions such as
troke, pneumonia, progressive renal failure, cancer, and
ulmonary embolism. None of the mortality that occurred
fter 30 days was related to the PHV or to the procedure.
fficacy and durability. The AVA increased to 1.7 cm2
onsistently after PHV implantation and did not signifi-
antly change even up to two years. Similarly, the mean
ransvalvular gradient decreased to 10 mm Hg post-
rocedure and remained at this value throughout the follow-
p. Left ventricular function improved as early as one week
ith the most significant increase seen in patients with
epressed myocardial function (15). This phenomenon is
ell described in the surgical literature after appropriate
election of patients with depressed ejection fraction for walve replacement (16). And though our patients were not
re-selected by dobutamine echocardiography, recovery of
eft ventricular dysfunction was seen in several cases, con-
istent with afterload mismatch pathophysiology.
Improvements in echocardiographic variables correlated
ith clinical improvement as well. All patients had symp-
omatic relief after the procedure, with the majority improv-
ng from NYHA functional class IV to class II. Obviously,
he largest amelioration of symptoms was seen in patients
ithout comorbidities that limited functional status such as
evere lung disease. In patients without PHV implantation,
mprovement in symptoms after only BAV were short lived.
atients either died of heart failure or had the return of class
V dyspnea by six months, which is consistent with previ-
usly published data on BAV (4).
uture directions. Future improvements in technique and
ardware will be directed at two different issues: improved
eliverability of the PHV via the retrograde approach and
esolution of adverse events that are related to PHV size.
urrently, a new, lower-profile system with a steerable
elivery catheter has been developed to revive the retrograde
pproach. The results of this new technology and the
oncomitant implantation of a larger PHV (26 mm) in a
eries of less severely ill patients are promising and should
oon be reported. In our series, we have been implanting
atients that have different size aortic annuli with one size
HV (23 mm). Keeping this limitation in mind, grade 3
aravalvular leak occurred in five patients (four in
-REVIVE, one in RECAST). The regurgitation was well
olerated, and all patients maintained an improved func-
ional class post-procedure (one patient has 10 months
ollow-up and paravalvular leak is now grade 2). In these
ases, however, a larger size prosthesis could have been
etter apposed to the native leaflets, resulting in less
egurgitation. Similarly, a larger PHV may have been
mportant in decreasing the risk of migration. Although this
roblem is less common than paravalvular leak, patients
ith a larger annulus and mild aortic valve calcification seem
o be at increased risk. Currently, we believe that patients
ith an aortic annulus 21 mm would benefit from a larger
ize PHV.
With increasing experience, complications related to
he procedure should decrease, and innovations in hard-
are should make PHV implantation technically less
emanding, with less risk to the patient. Soon, multi-
enter trials will begin in Europe to study the feasibility,
afety, and efficacy of PHV implantation in patients at
igh surgical risk with less severe comorbidity. In this
ohort, we hope to study the long-term performance of
he PHV and the continuing clinical benefits of this
echnique. With continued advances in this field, percu-
aneous aortic valve implantation should become a very
ealistic way of treating a select population of patients
ith degenerative aortic stenosis in the near future.
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